In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Market Share: Drug Plan Starts With Big Four

Executive Summary

Pharmaceutical manufacturers interested in maximizing their market share under the new Medicare drug benefit in 2006 should focus on four insurers likely to take the lion's share of enrollment. Dozens of plans are entering the market, but UnitedHealth Group, Wellpoint, Humana and Wellcare will start with a big edge in enrollment as of January 1. An analysis by The RPM Report explains why.

You may also be interested in...

A Second-Half Story: Medicare Plans, Wall Street and the Future of Part D

The three most aggressive Medicare Part D bidders are thrilled with how their bets are paying off so far. The next challenge: translating market share into profits and proving to investors that they can make Medicare pay in the long term.

Preparing for Year Two of Part D: CMS Puts a Premium on Stability

The bids are in for insurers participating in the 2007 Medicare plan year. A last-minute rules change by CMS likely means fewer changes in the market for the second year.

The Big Three and Medicare: A Risky Proposition

As Part D gets under way, it is increasingly clear that the new Medicare drug benefit poses serious threats to Medco, Caremark and Express Scripts.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts